Key Points
- Progyny COO Melissa Cummings sold 1,879 shares at an average price of $28, generating $52,612. The sale was made under a pre-arranged Rule 10b5-1 trading plan, leaving her with 66,496 shares.
- Progyny recently reported quarterly EPS of $0.55, beating estimates of $0.33, while revenue rose 5.3% year over year to $350.51 million. The company provided Q3 and full-year 2026 earnings guidance.
- Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $34.36 versus the stock’s recent price of $26.86; institutional investors own approximately 94.93% of outstanding shares.
Progyny, Inc. (NASDAQ:PGNY - Get Free Report) COO Melissa Cummings sold 1,879 shares of Progyny stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the transaction, the chief operating officer directly owned 66,496 shares in the company, valued at approximately $1,861,888. The trade was a 2.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Progyny Price Performance
Shares of NASDAQ:PGNY traded down $0.59 during mid-day trading on Friday, reaching $26.86. 919,547 shares of the company traded hands, compared to its average volume of 1,253,538. The company's 50 day moving average price is $26.40 and its 200-day moving average price is $25.46. The firm has a market cap of $2.06 billion, a PE ratio of 29.20, a PEG ratio of 1.90 and a beta of 1.02. Progyny, Inc. has a 52 week low of $16.10 and a 52 week high of $33.06.
Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.33 by $0.22. Progyny had a net margin of 6.00% and a return on equity of 15.98%. The company had revenue of $350.51 million during the quarter, compared to analyst estimates of $349.05 million. During the same period in the prior year, the firm posted $0.19 EPS. The firm's quarterly revenue was up 5.3% compared to the same quarter last year. Progyny has set its Q3 2026 guidance at 0.500-0.520 EPS and its FY 2026 guidance at 2.040-2.100 EPS. On average, research analysts predict that Progyny, Inc. will post 1.25 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of analysts have recently issued reports on PGNY shares. Zacks Research raised shares of Progyny from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, July 8th. Citizens Jmp lifted their target price on shares of Progyny from $31.00 to $33.00 and gave the company a "market outperform" rating in a research note on Tuesday, September 8th. Weiss Ratings upgraded shares of Progyny from a "hold (c)" rating to a "hold (c+)" rating in a research note on Thursday, October 8th. Wall Street Zen raised shares of Progyny from a "buy" rating to a "strong-buy" rating in a report on Saturday, September 19th. Finally, Canaccord Genuity Group set a $35.00 target price on shares of Progyny in a report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $34.36.
Read Our Latest Stock Report on PGNY
Institutional Trading of Progyny
Several institutional investors have recently made changes to their positions in the business. BlackRock Inc. purchased a new position in Progyny in the 2nd quarter worth approximately $334,426,000. Fort Washington Investment Advisors Inc. OH boosted its stake in Progyny by 46.9% in the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 2,693,393 shares of the company's stock worth $45,734,000 after purchasing an additional 859,289 shares during the period. Bank of America Corp DE boosted its stake in Progyny by 75.3% in the 1st quarter. Bank of America Corp DE now owns 1,190,996 shares of the company's stock worth $20,223,000 after purchasing an additional 511,609 shares during the period. River Road Asset Management LLC grew its holdings in Progyny by 13.9% during the 4th quarter. River Road Asset Management LLC now owns 687,824 shares of the company's stock valued at $17,663,000 after buying an additional 83,912 shares in the last quarter. Finally, William Blair Investment Management LLC bought a new stake in shares of Progyny during the second quarter valued at approximately $16,807,000. Hedge funds and other institutional investors own 94.93% of the company's stock.
Progyny Company Profile
(
Get Free Report)
Progyny, Inc (NASDAQ: PGNY) is a fertility and family-building benefits company that helps employers provide reproductive health services to their employees. Its platform is designed to support individuals and families navigating fertility treatment, preservation, adoption, surrogacy and related family-building needs.
The company offers an integrated benefits solution that combines personalized care navigation with access to a network of fertility specialists and treatment providers. Progyny also provides pharmacy benefits through Progyny Rx, helping members obtain and manage medications commonly used in fertility treatments.
Progyny primarily serves employer-sponsored benefit programs in the United States.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
